Problems tracking success of disease campaigns in LDCs

23 February 2009

Attempts to eradicate or at least reduce disease burdens in less-developed countries have faced another blow to their credibility,  with the appearance of a report by William Easterly, co-director of the  US New York University's Development Research Institute, into claims of  success in countering malaria. The Bill & Melinda Gates Foundation,  which already attracts criticism over fears that its sheer size can  create distortions to the local economies where it operates, issued data  claiming that Zambia had experienced a 50% drop in child malaria rates.  Similar improvements were alleged to have been made in Ethiopia.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight